25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Arovella Therapeutics Ltd
Buy, Hold or Sell?

Let's analyze Arovella together

I guess you are interested in Arovella Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arovella Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arovella Therapeutics Ltd

I send you an email if I find something interesting about Arovella Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Arovella (30 sec.)










1.2. What can you expect buying and holding a share of Arovella? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.02
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
A$0.01
Return On Investment
3.7%

For what price can you sell your share?

Current Price per Share
A$0.19
Expected price per share
A$0.17 - A$0.205
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arovella (5 min.)




Live pricePrice per Share (EOD)
A$0.19
Intrinsic Value Per Share
A$-0.09 - A$-0.05
Total Value Per Share
A$-0.08 - A$-0.04

2.2. Growth of Arovella (5 min.)




Is Arovella growing?

Current yearPrevious yearGrowGrow %
How rich?$7.5m$2.6m$2.1m44.0%

How much money is Arovella making?

Current yearPrevious yearGrowGrow %
Making money-$1.7m-$2.5m$760.9k42.5%
Net Profit Margin-39,892.8%-12,263.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Arovella (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#661 / 959

Most Revenue
#650 / 959

Most Profit
#280 / 959

Most Efficient
#929 / 959
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arovella?

Welcome investor! Arovella's management wants to use your money to grow the business. In return you get a share of Arovella.

First you should know what it really means to hold a share of Arovella. And how you can make/lose money.

Speculation

The Price per Share of Arovella is A$0.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arovella.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arovella, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arovella.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-0.8%0.00-0.9%0.00-0.8%0.00-0.9%0.00-0.7%
Usd Book Value Change Per Share0.000.0%0.000.6%0.00-0.3%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.6%0.00-0.3%0.000.0%0.000.0%
Usd Price Per Share0.09-0.08-0.03-0.04-0.03-
Price to Earnings Ratio-15.40--12.18--3.94--6.42--8.60-
Price-to-Total Gains Ratio-3,863.86--2,280.87--4,377,306.25--2,553,438.00-
Price to Book Ratio13.17-22.22-10.15-10.50-5.96-
Price-to-Total Gains Ratio-3,863.86--2,280.87--4,377,306.25--2,553,438.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.127015
Number of shares7873
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (7873 shares)9.28-0.69
Gains per Year (7873 shares)37.11-2.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1037270-3-13
2074640-5-16
301111010-8-19
401481380-11-22
501861750-14-25
602232120-16-28
702602490-19-31
802972860-22-34
903343230-25-37
1003713600-27-40

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.048.00.00.0%
Book Value Change Per Share1.02.01.025.0%2.07.03.016.7%4.010.06.020.0%7.017.016.017.5%10.019.019.020.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share1.02.01.025.0%2.07.03.016.7%4.010.06.020.0%7.017.016.017.5%10.019.019.020.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arovella Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-100%-0.0010%0.0000%0.0000%
Book Value Per Share--0.0110.007+56%0.004+179%0.006+77%0.011+1%
Current Ratio--6.4464.408+46%2.875+124%3.188+102%2.798+130%
Debt To Asset Ratio--0.1550.283-45%0.291-47%0.261-41%0.217-29%
Debt To Equity Ratio--0.1830.441-58%0.411-55%0.377-51%0.300-39%
Dividend Per Share----0%-0%-0%-0%
Eps---0.002-0.003+12%-0.002+6%-0.003+17%-0.002-16%
Free Cash Flow Per Share---0.002-0.002-4%-0.002+10%-0.002-12%-0.001-41%
Free Cash Flow To Equity Per Share--0.0040.002+116%0.000+109%0.000+772%0.000+1060%
Gross Profit Margin--1.1491.196-4%1.236-7%1.203-5%1.102+4%
Intrinsic Value_10Y_max---0.055--------
Intrinsic Value_10Y_min---0.086--------
Intrinsic Value_1Y_max---0.005--------
Intrinsic Value_1Y_min---0.009--------
Intrinsic Value_3Y_max---0.015--------
Intrinsic Value_3Y_min---0.027--------
Intrinsic Value_5Y_max---0.026--------
Intrinsic Value_5Y_min---0.044--------
Market Cap200685600.000+26%147873600.000124900380.000+18%40137120.000+268%58594914.000+152%40821035.400+262%
Net Profit Margin---564.737-398.928-29%-122.638-78%-138.778-75%-73.094-87%
Operating Margin---570.917-461.225-19%-94.289-83%-141.252-75%-72.175-87%
Operating Ratio--479.638414.900+16%110.252+335%136.811+251%72.690+560%
Pb Ratio17.874+26%13.17022.223-41%10.152+30%10.498+25%5.964+121%
Pe Ratio-20.904-36%-15.403-12.176-21%-3.940-74%-6.425-58%-8.605-44%
Price Per Share0.190+26%0.1400.118+18%0.038+268%0.055+152%0.039+262%
Price To Free Cash Flow Ratio-22.967-36%-16.923-14.960-12%-4.751-72%-8.657-49%-11.202-34%
Quick Ratio--6.2304.218+48%2.648+135%2.992+108%2.374+162%
Return On Assets---0.181-0.368+104%-0.680+276%-0.415+130%-0.242+34%
Return On Equity---0.214-0.579+171%-0.967+352%-0.586+174%-0.336+57%
Total Gains Per Share---0.002-100%-0.0010%0.0000%0.0000%
Usd Book Value--7505949.4204802050.089+56%2689619.168+179%4251110.526+77%7417804.870+1%
Usd Book Value Change Per Share---0.001-100%-0.0010%0.0000%0.0000%
Usd Book Value Per Share--0.0070.005+56%0.003+179%0.004+77%0.007+1%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.002-0.002+12%-0.002+6%-0.002+17%-0.001-16%
Usd Free Cash Flow---1460340.924-1400560.312-4%-1604491.752+10%-1292400.989-12%-863947.707-41%
Usd Free Cash Flow Per Share---0.001-0.001-4%-0.002+10%-0.001-12%-0.001-41%
Usd Free Cash Flow To Equity Per Share--0.0030.001+116%0.000+109%0.000+772%0.000+1060%
Usd Market Cap134158323.600+26%98853501.60083495904.030+18%26831664.720+268%39170700.009+152%27288862.165+262%
Usd Price Per Share0.127+26%0.0940.079+18%0.025+268%0.037+152%0.026+262%
Usd Profit---1604488.911-1791399.672+12%-2552337.512+59%-2052175.372+28%-1432237.117-11%
Usd Revenue--2841.125165255.038-98%189390.897-98%138660.972-98%306804.950-99%
Usd Total Gains Per Share---0.001-100%-0.0010%0.0000%0.0000%
 EOD+5 -2MRQTTM+20 -13YOY+22 -75Y+19 -1010Y+17 -12

3.3 Fundamental Score

Let's check the fundamental score of Arovella Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-20.904
Price to Book Ratio (EOD)Between0-117.874
Net Profit Margin (MRQ)Greater than0-564.737
Operating Margin (MRQ)Greater than0-570.917
Quick Ratio (MRQ)Greater than16.230
Current Ratio (MRQ)Greater than16.446
Debt to Asset Ratio (MRQ)Less than10.155
Debt to Equity Ratio (MRQ)Less than10.183
Return on Equity (MRQ)Greater than0.15-0.214
Return on Assets (MRQ)Greater than0.05-0.181
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Arovella Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.230
Ma 20Greater thanMa 500.185
Ma 50Greater thanMa 1000.166
Ma 100Greater thanMa 2000.158
OpenGreater thanClose0.187
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Arovella Therapeutics Ltd

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Fundamental data was last updated by Penke on 2024-11-01 21:32:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arovella earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • A Net Profit Margin of -56,473.7% means that $-564.74 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arovella Therapeutics Ltd:

  • The MRQ is -56,473.7%. The company is making a huge loss. -2
  • The TTM is -39,892.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-56,473.7%TTM-39,892.8%-16,580.9%
TTM-39,892.8%YOY-12,263.8%-27,629.0%
TTM-39,892.8%5Y-13,877.8%-26,015.1%
5Y-13,877.8%10Y-7,309.4%-6,568.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56,473.7%-135.3%-56,338.4%
TTM-39,892.8%-204.4%-39,688.4%
YOY-12,263.8%-207.5%-12,056.3%
5Y-13,877.8%-353.2%-13,524.6%
10Y-7,309.4%-464.5%-6,844.9%
4.3.1.2. Return on Assets

Shows how efficient Arovella is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • -18.1% Return on Assets means that Arovella generated $-0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arovella Therapeutics Ltd:

  • The MRQ is -18.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -36.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.1%TTM-36.8%+18.7%
TTM-36.8%YOY-68.0%+31.2%
TTM-36.8%5Y-41.5%+4.7%
5Y-41.5%10Y-24.2%-17.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.1%-10.7%-7.4%
TTM-36.8%-11.8%-25.0%
YOY-68.0%-11.0%-57.0%
5Y-41.5%-12.6%-28.9%
10Y-24.2%-14.3%-9.9%
4.3.1.3. Return on Equity

Shows how efficient Arovella is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • -21.4% Return on Equity means Arovella generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arovella Therapeutics Ltd:

  • The MRQ is -21.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -57.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.4%TTM-57.9%+36.5%
TTM-57.9%YOY-96.7%+38.7%
TTM-57.9%5Y-58.6%+0.7%
5Y-58.6%10Y-33.6%-25.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.4%-13.5%-7.9%
TTM-57.9%-15.9%-42.0%
YOY-96.7%-13.5%-83.2%
5Y-58.6%-18.5%-40.1%
10Y-33.6%-19.0%-14.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arovella Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arovella is operating .

  • Measures how much profit Arovella makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • An Operating Margin of -57,091.7% means the company generated $-570.92  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arovella Therapeutics Ltd:

  • The MRQ is -57,091.7%. The company is operating very inefficient. -2
  • The TTM is -46,122.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-57,091.7%TTM-46,122.5%-10,969.2%
TTM-46,122.5%YOY-9,428.9%-36,693.6%
TTM-46,122.5%5Y-14,125.2%-31,997.3%
5Y-14,125.2%10Y-7,217.5%-6,907.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-57,091.7%-277.1%-56,814.6%
TTM-46,122.5%-312.4%-45,810.1%
YOY-9,428.9%-223.5%-9,205.4%
5Y-14,125.2%-384.9%-13,740.3%
10Y-7,217.5%-494.6%-6,722.9%
4.3.2.2. Operating Ratio

Measures how efficient Arovella is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 479.64 means that the operating costs are $479.64 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 479.638. The company is inefficient in keeping operating costs low. -1
  • The TTM is 414.900. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ479.638TTM414.900+64.739
TTM414.900YOY110.252+304.648
TTM414.9005Y136.811+278.088
5Y136.81110Y72.690+64.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ479.6382.842+476.796
TTM414.9003.179+411.721
YOY110.2523.301+106.951
5Y136.8114.794+132.017
10Y72.6906.520+66.170
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arovella Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arovella is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.45 means the company has $6.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 6.446. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.408. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.446TTM4.408+2.038
TTM4.408YOY2.875+1.533
TTM4.4085Y3.188+1.220
5Y3.18810Y2.798+0.389
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4463.783+2.663
TTM4.4083.923+0.485
YOY2.8754.715-1.840
5Y3.1885.960-2.772
10Y2.7986.285-3.487
4.4.3.2. Quick Ratio

Measures if Arovella is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • A Quick Ratio of 6.23 means the company can pay off $6.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 6.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.218. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.230TTM4.218+2.012
TTM4.218YOY2.648+1.570
TTM4.2185Y2.992+1.226
5Y2.99210Y2.374+0.618
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2303.349+2.881
TTM4.2183.522+0.696
YOY2.6484.691-2.043
5Y2.9925.927-2.935
10Y2.3746.469-4.095
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arovella Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arovella assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arovella to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Arovella assets are financed with 15.5% credit (debt) and the remaining percentage (100% - 15.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 0.155. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.283. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.155TTM0.283-0.128
TTM0.283YOY0.291-0.008
TTM0.2835Y0.261+0.022
5Y0.26110Y0.217+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1550.338-0.183
TTM0.2830.347-0.064
YOY0.2910.309-0.018
5Y0.2610.365-0.104
10Y0.2170.380-0.163
4.5.4.2. Debt to Equity Ratio

Measures if Arovella is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.3% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 0.183. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.441. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.183TTM0.441-0.258
TTM0.441YOY0.411+0.030
TTM0.4415Y0.377+0.064
5Y0.37710Y0.300+0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1830.389-0.206
TTM0.4410.437+0.004
YOY0.4110.375+0.036
5Y0.3770.450-0.073
10Y0.3000.488-0.188
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arovella generates.

  • Above 15 is considered overpriced but always compare Arovella to the Biotechnology industry mean.
  • A PE ratio of -15.40 means the investor is paying $-15.40 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is -20.904. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.403. Based on the earnings, the company is expensive. -2
  • The TTM is -12.176. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.904MRQ-15.403-5.501
MRQ-15.403TTM-12.176-3.227
TTM-12.176YOY-3.940-8.236
TTM-12.1765Y-6.425-5.751
5Y-6.42510Y-8.605+2.180
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.904-2.431-18.473
MRQ-15.403-2.454-12.949
TTM-12.176-2.994-9.182
YOY-3.940-3.435-0.505
5Y-6.425-6.005-0.420
10Y-8.605-6.275-2.330
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is -22.967. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -16.923. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.960. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-22.967MRQ-16.923-6.044
MRQ-16.923TTM-14.960-1.963
TTM-14.960YOY-4.751-10.209
TTM-14.9605Y-8.657-6.303
5Y-8.65710Y-11.202+2.545
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-22.967-3.231-19.736
MRQ-16.923-3.234-13.689
TTM-14.960-3.528-11.432
YOY-4.751-4.567-0.184
5Y-8.657-8.099-0.558
10Y-11.202-8.945-2.257
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arovella is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 13.17 means the investor is paying $13.17 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is 17.874. Based on the equity, the company is expensive. -2
  • The MRQ is 13.170. Based on the equity, the company is expensive. -2
  • The TTM is 22.223. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD17.874MRQ13.170+4.704
MRQ13.170TTM22.223-9.053
TTM22.223YOY10.152+12.071
TTM22.2235Y10.498+11.726
5Y10.49810Y5.964+4.533
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.8741.938+15.936
MRQ13.1701.983+11.187
TTM22.2232.193+20.030
YOY10.1522.392+7.760
5Y10.4983.608+6.890
10Y5.9644.220+1.744
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets13,285
Total Liabilities2,057
Total Stockholder Equity11,228
 As reported
Total Liabilities 2,057
Total Stockholder Equity+ 11,228
Total Assets = 13,285

Assets

Total Assets13,285
Total Current Assets13,154
Long-term Assets131
Total Current Assets
Cash And Cash Equivalents 12,714
Other Current Assets 229
Total Current Assets  (as reported)13,154
Total Current Assets  (calculated)12,944
+/- 210
Long-term Assets
Property Plant Equipment 131
Other Assets 0
Long-term Assets  (as reported)131
Long-term Assets  (calculated)131
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities2,041
Long-term Liabilities16
Total Stockholder Equity11,228
Total Current Liabilities
Short-term Debt 785
Accounts payable 984
Other Current Liabilities 136
Total Current Liabilities  (as reported)2,041
Total Current Liabilities  (calculated)1,905
+/- 136
Long-term Liabilities
Long-term Liabilities  (as reported)16
Long-term Liabilities  (calculated)0
+/- 16
Total Stockholder Equity
Common Stock104,296
Retained Earnings -95,506
Accumulated Other Comprehensive Income 2,438
Total Stockholder Equity (as reported)11,228
Total Stockholder Equity (calculated)11,228
+/-0
Other
Cash and Short Term Investments 12,714
Common Stock Shares Outstanding 982,332
Current Deferred Revenue136
Liabilities and Stockholders Equity 13,285
Net Debt -12,714
Net Working Capital 11,113



6.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-30
> Total Assets 
4,653
16,096
14,951
16,629
20,998
16,064
16,611
11,902
13,526
9,755
10,157
10,157
10,729
10,729
21,329
21,329
20,347
20,347
19,264
19,264
22,821
22,821
20,127
20,127
19,515
19,515
19,005
19,005
20,016
20,016
18,287
18,287
16,642
16,642
19,314
19,314
16,253
16,253
8,100
8,100
6,707
6,707
10,410
10,410
10,687
10,687
8,421
8,421
9,212
9,212
5,861
5,861
5,471
5,471
5,328
5,328
13,285
13,285
13,28513,2855,3285,3285,4715,4715,8615,8619,2129,2128,4218,42110,68710,68710,41010,4106,7076,7078,1008,10016,25316,25319,31419,31416,64216,64218,28718,28720,01620,01619,00519,00519,51519,51520,12720,12722,82122,82119,26419,26420,34720,34721,32921,32910,72910,72910,15710,1579,75513,52611,90216,61116,06420,99816,62914,95116,0964,653
   > Total Current Assets 
1,220
7,357
5,556
6,212
7,869
6,234
8,009
2,793
5,779
3,054
2,427
2,427
2,432
2,432
8,838
8,838
7,485
7,485
5,992
5,992
9,344
9,344
6,304
6,304
5,293
5,293
4,262
4,262
4,610
4,610
2,566
2,566
1,071
1,071
3,188
3,188
5,595
5,595
2,817
2,817
2,035
2,035
5,760
5,760
7,343
7,343
4,770
4,770
6,588
6,588
4,029
4,029
5,421
5,421
5,177
5,177
13,154
13,154
13,15413,1545,1775,1775,4215,4214,0294,0296,5886,5884,7704,7707,3437,3435,7605,7602,0352,0352,8172,8175,5955,5953,1883,1881,0711,0712,5662,5664,6104,6104,2624,2625,2935,2936,3046,3049,3449,3445,9925,9927,4857,4858,8388,8382,4322,4322,4272,4273,0545,7792,7938,0096,2347,8696,2125,5567,3571,220
       Cash And Cash Equivalents 
791
3,781
1,827
975
835
486
2,899
859
3,561
1,590
1,067
1,067
753
753
5,527
5,527
3,990
3,990
3,050
3,050
6,252
6,252
3,396
3,396
2,449
2,449
1,220
1,220
1,770
1,770
622
622
98
98
2,765
2,765
4,314
4,314
2,389
2,389
977
977
5,469
5,469
6,717
6,717
4,386
4,386
6,071
6,071
3,512
3,512
5,175
5,175
4,763
4,763
12,714
12,714
12,71412,7144,7634,7635,1755,1753,5123,5126,0716,0714,3864,3866,7176,7175,4695,4699779772,3892,3894,3144,3142,7652,76598986226221,7701,7701,2201,2202,4492,4493,3963,3966,2526,2523,0503,0503,9903,9905,5275,5277537531,0671,0671,5903,5618592,8994868359751,8273,781791
       Short-term Investments 
0
0
0
1,513
1,885
117
362
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000003621171,8851,513000
       Net Receivables 
223
1,124
1,356
1,012
1,574
2,285
1,456
396
456
671
339
339
461
635
1,876
1,876
750
931
606
606
669
1,319
1,294
1,294
773
1,517
1,639
1,639
928
1,608
15
15
46
791
266
266
196
1,121
340
340
216
869
62
62
10
534
22
22
36
36
18
18
10
10
0
111
0
0
00111010101818363622225341062628692163403401,1211962662667914615151,6089281,6391,6391,5177731,2941,2941,3196696066069317501,8761,8766354613393396714563961,4562,2851,5741,0121,3561,124223
       Inventory 
201
2,364
2,186
2,698
3,574
2,935
0
0
642
716
639
639
803
803
1,017
1,017
1,788
1,788
2,030
2,030
1,541
1,541
1,456
1,456
1,132
1,132
1,168
1,168
1,111
1,111
264
264
98
98
73
73
45
45
22
22
22
22
22
22
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000002222222222224545737398982642641,1111,1111,1681,1681,1321,1321,4561,4561,5411,5412,0302,0301,7881,7881,0171,017803803639639716642002,9353,5742,6982,1862,364201
       Other Current Assets 
5
88
188
15
0
412
0
0
1,121
77
382
382
415
241
418
418
957
776
306
306
883
233
158
158
939
195
235
235
801
122
1,665
1,665
829
84
85
85
1,040
115
66
66
819
166
206
206
616
92
362
362
480
480
499
499
236
202
414
302
229
229
2292293024142022364994994804803623629261620620616681966661151,0408585848291,6651,665122801235235195939158158233883306306776957418418241415382382771,12100412015188885
   > Long-term Assets 
3,433
8,739
9,395
10,417
13,130
9,830
8,602
9,110
7,747
6,700
101
101
8,297
8,297
12,491
12,491
12,862
12,862
13,271
13,271
13,476
13,476
13,824
13,824
14,222
14,222
14,743
14,743
15,405
15,405
15,722
15,722
15,571
15,571
16,125
16,125
10,658
10,658
5,284
5,284
4,673
4,673
4,651
4,651
3,344
3,344
3,651
3,651
2,625
2,625
1,832
1,832
50
50
151
151
131
131
13113115115150501,8321,8322,6252,6253,6513,6513,3443,3444,6514,6514,6734,6735,2845,28410,65810,65816,12516,12515,57115,57115,72215,72215,40515,40514,74314,74314,22214,22213,82413,82413,47613,47613,27113,27112,86212,86212,49112,4918,2978,2971011016,7007,7479,1108,6029,83013,13010,4179,3958,7393,433
       Property Plant Equipment 
1,367
1,863
1,904
2,266
2,441
3,794
4,170
5,935
5,981
6,700
92
92
117
8,297
162
162
312
312
354
354
389
389
318
318
272
272
271
271
232
232
210
210
173
173
360
360
367
367
519
519
422
422
442
442
433
433
461
461
371
371
219
219
50
50
151
151
131
131
13113115115150502192193713714614614334334424424224225195193673673603601731732102102322322712712722723183183893893543543123121621628,29711792926,7005,9815,9354,1703,7942,4412,2661,9041,8631,367
       Goodwill 
0
4,085
4,177
4,635
6,048
2,421
890
966
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000009668902,4216,0484,6354,1774,0850
       Intangible Assets 
2,066
2,476
2,503
2,503
2,493
2,493
2,193
2,193
1,766
0
9
9
0
0
2,051
2,051
0
12,549
0
0
0
13,088
0
0
0
13,951
0
0
0
15,173
0
0
0
15,399
0
0
132
10,291
0
4,208
132
4,251
132
132
132
2,911
132
132
2,253
2,253
132
132
0
0
0
0
0
0
0000001321322,2532,2531321322,9111321321324,2511324,208010,2911320015,39900015,17300013,95100013,08800012,54902,0512,051009901,7662,1932,1932,4932,4932,5032,5032,4762,066
       Other Assets 
0
0
0
0
0
0
0
0
0
0
7,629
7,629
8,180
0
10,277
10,277
12,549
0
12,917
12,917
13,088
0
13,506
13,506
13,951
0
14,471
14,471
15,173
0
15,512
15,512
15,399
0
15,765
15,765
10,158
0
4,765
0
4,119
0
4,076
0
2,779
0
3,057
0
0
0
1,481
1,481
0
0
0
0
0
0
0000001,4811,4810003,05702,77904,07604,11904,765010,15815,76515,765015,39915,51215,512015,17314,47114,471013,95113,50613,506013,08812,91712,917012,54910,27710,27708,1807,6297,6290000000000
> Total Liabilities 
885
2,821
3,227
3,278
6,671
5,554
7,769
3,557
2,494
2,743
3,931
3,931
4,039
4,039
4,718
4,718
4,355
4,355
3,719
3,719
3,520
3,520
3,096
3,096
2,909
2,909
3,297
3,297
3,163
3,163
3,625
3,625
5,178
5,178
2,129
2,129
2,276
2,276
1,822
1,822
2,572
2,572
1,565
1,565
1,706
1,706
3,100
3,100
1,595
1,595
1,595
1,603
1,682
1,691
2,184
2,195
2,057
2,057
2,0572,0572,1952,1841,6911,6821,6031,5951,5951,5953,1003,1001,7061,7061,5651,5652,5722,5721,8221,8222,2762,2762,1292,1295,1785,1783,6253,6253,1633,1633,2973,2972,9092,9093,0963,0963,5203,5203,7193,7194,3554,3554,7184,7184,0394,0393,9313,9312,7432,4943,5577,7695,5546,6713,2783,2272,821885
   > Total Current Liabilities 
617
2,287
2,763
1,804
5,103
5,334
5,933
2,283
2,494
2,743
2,606
2,606
3,439
3,439
2,818
2,818
2,480
2,480
3,719
3,719
3,520
3,520
1,366
1,366
2,909
2,909
3,297
3,297
1,361
1,361
1,572
1,572
3,835
3,835
1,203
1,203
1,349
1,349
1,271
1,271
2,022
2,022
1,519
1,519
1,695
1,695
2,982
2,982
1,509
1,509
1,595
1,595
1,682
1,682
2,184
2,184
2,041
2,041
2,0412,0412,1842,1841,6821,6821,5951,5951,5091,5092,9822,9821,6951,6951,5191,5192,0222,0221,2711,2711,3491,3491,2031,2033,8353,8351,5721,5721,3611,3613,2973,2972,9092,9091,3661,3663,5203,5203,7193,7192,4802,4802,8182,8183,4393,4392,6062,6062,7432,4942,2835,9335,3345,1031,8042,7632,287617
       Short-term Debt 
229
1,538
2,013
1,124
2,549
3,233
2,468
744
1,194
701
0
0
562
562
883
883
0
0
1,875
1,875
1,725
1,725
0
0
1,730
1,730
1,730
1,730
0
0
0
0
2,003
2,023
0
0
0
36
0
95
0
81
0
76
0
76
0
63
67
67
0
37
0
0
0
0
0
785
785000003706767630760760810950360002,0232,00300001,7301,7301,7301,730001,7251,7251,8751,87500883883562562007011,1947442,4683,2332,5491,1242,0131,538229
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0000000010000000000000000000000000000000000000000000000000
       Accounts payable 
150
620
517
291
2,318
1,314
1,737
1,336
947
979
2,568
2,568
968
968
1,936
1,936
1,681
1,681
1,844
1,844
1,578
1,578
1,366
1,366
994
994
1,567
1,567
1,361
1,361
561
561
353
353
1,182
1,182
480
512
1,176
1,176
732
732
493
493
227
227
696
696
752
752
778
778
773
773
1,611
1,611
984
984
9849841,6111,6117737737787787527526966962272274934937327321,1761,1765124801,1821,1823533535615611,3611,3611,5671,5679949941,3661,3661,5781,5781,8441,8441,6811,6811,9361,9369689682,5682,5689799471,3361,7371,3142,318291517620150
       Other Current Liabilities 
238
128
233
389
236
250
99
203
353
1,062
37
37
1,909
1,909
0
0
799
799
0
0
217
217
0
0
186
186
1,730
1,730
0
0
1,012
1,012
1,480
1,459
21
21
868
801
95
95
1,290
333
1,026
750
1,467
200
2,285
1,752
342
348
818
611
909
606
573
429
1,057
136
1361,0574295736069096118183483421,7522,2852001,4677501,0263331,290959580186821211,4591,4801,0121,012001,7301,7301861860021721700799799001,9091,90937371,06235320399250236389233128238
   > Long-term Liabilities 
268
534
463
1,474
1,568
220
1,835
1,274
0
0
1,325
1,325
600
600
1,900
1,900
1,875
1,875
0
0
0
0
1,730
1,730
0
0
0
0
1,803
1,803
2,052
2,052
1,342
1,342
926
926
927
927
551
551
550
550
46
46
11
11
118
118
87
87
0
7
0
9
0
11
16
16
161611090708787118118111146465505505515519279279269261,3421,3422,0522,0521,8031,80300001,7301,73000001,8751,8751,9001,9006006001,3251,325001,2741,8352201,5681,474463534268
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
0
41
0
4
0
38
0
3
0
112
0
77
0
0
0
0
0
0
0
0
0000000077011203038040410170000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
9
9
0
0
0
0
0000997700000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,481
1,481
0
0
0
0
0
0
0000001,4811,48100000000000000000000000000000000000000000000000000
> Total Stockholder Equity
3,767
13,275
11,725
13,351
14,327
10,295
8,842
8,346
11,032
7,012
6,227
6,227
6,690
6,690
14,560
14,560
13,949
13,949
13,515
13,515
17,269
17,269
17,031
17,031
16,606
16,606
15,707
15,707
16,852
16,852
14,663
14,663
11,465
11,465
17,185
17,185
13,977
13,977
6,278
6,278
4,135
4,135
8,846
8,846
8,982
8,982
5,321
5,321
7,617
7,617
4,258
4,258
3,780
3,780
3,133
3,133
11,228
11,228
11,22811,2283,1333,1333,7803,7804,2584,2587,6177,6175,3215,3218,9828,9828,8468,8464,1354,1356,2786,27813,97713,97717,18517,18511,46511,46514,66314,66316,85216,85215,70715,70716,60616,60617,03117,03117,26917,26913,51513,51513,94913,94914,56014,5606,6906,6906,2276,2277,01211,0328,3468,84210,29514,32713,35111,72513,2753,767
   Common Stock
5,905
16,380
16,759
17,704
20,818
26,377
27,793
31,486
38,621
38,858
38,964
38,964
40,129
40,129
48,136
48,136
48,945
48,945
50,397
50,397
55,574
55,574
55,705
55,705
55,717
55,717
55,735
55,735
57,139
57,139
57,167
57,167
57,205
57,205
63,755
63,755
67,386
67,386
67,386
67,386
67,386
67,386
73,700
73,700
77,003
77,003
77,042
77,042
83,536
83,536
83,639
83,639
88,872
88,872
91,779
91,779
104,296
104,296
104,296104,29691,77991,77988,87288,87283,63983,63983,53683,53677,04277,04277,00377,00373,70073,70067,38667,38667,38667,38667,38667,38663,75563,75557,20557,20557,16757,16757,13957,13955,73555,73555,71755,71755,70555,70555,57455,57450,39750,39748,94548,94548,13648,13640,12940,12938,96438,96438,85838,62131,48627,79326,37720,81817,70416,75916,3805,905
   Retained Earnings -95,506-95,506-90,748-90,748-87,055-87,055-80,815-80,815-77,025-77,025-72,422-72,422-68,472-68,472-66,577-66,577-64,889-64,881-63,411-63,411-55,712-55,712-48,787-48,787-47,917-47,917-44,681-44,681-42,458-42,458-42,136-42,136-41,219-41,219-40,744-40,744-38,932-38,932-37,510-37,510-35,565-35,565-33,845-33,845-33,513-33,513-34,076-34,076-33,110-28,673-24,249-19,393-16,225-6,591-4,584-5,034-3,105-2,138
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
1,338
1,338
0
0
0
0
0
0
0
0
0
0
2,071
2,071
0
0
2,109
2,109
0
0
0
0
0
0
2,217
2,217
2,303
0
2,303
0
0
0
0
0
451
0
0
0
1,105
0
0
1,434
0
1,964
0
0
0
0
00001,96401,434001,105000451000002,30302,3032,2172,2170000002,1092,109002,0712,07100000000001,3381,3380000000000



6.3. Balance Sheets

All numbers in thousands.




6.4. Cash Flows

All numbers in thousands.




6.5. Income Statements

All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-06-30. All numbers in thousands.

Gross Profit (+$)
totalRevenue17
Cost of Revenue-43
Gross Profit-26-26
 
Operating Income (+$)
Gross Profit-26
Operating Expense-10,828
Operating Income-10,811-10,854
 
Operating Expense (+$)
Research Development6,735
Selling General Administrative2,771
Selling And Marketing Expenses0
Operating Expense10,8289,506
 
Net Interest Income (+$)
Interest Income0
Interest Expense-9
Other Finance Cost-9
Net Interest Income0
 
Pretax Income (+$)
Operating Income-10,811
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-8,746-12,746
EBIT - interestExpense = -8,746
-10,681
-8,737
Interest Expense9
Earnings Before Interest and Taxes (EBIT)-8,737-8,737
Earnings Before Interest and Taxes (EBITDA)-8,694
 
After tax Income (+$)
Income Before Tax-8,746
Tax Provision-0
Net Income From Continuing Ops0-8,746
Net Income-8,746
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses10,828
Total Other Income/Expenses Net1,9350
 

Technical Analysis of Arovella
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arovella. The general trend of Arovella is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arovella's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arovella Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.195 < 0.205 < 0.205.

The bearish price targets are: 0.17 > 0.17 > 0.17.

Tweet this
Arovella Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arovella Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arovella Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arovella Therapeutics Ltd. The current macd is 0.00511893.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arovella price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arovella. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arovella price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Arovella Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartArovella Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arovella Therapeutics Ltd. The current adx is 22.77.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arovella shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Arovella Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arovella Therapeutics Ltd. The current sar is 0.19287024.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Arovella Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arovella Therapeutics Ltd. The current rsi is 58.23. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Arovella Therapeutics Ltd Daily Relative Strength Index (RSI) ChartArovella Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arovella Therapeutics Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arovella price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Arovella Therapeutics Ltd Daily Stochastic Oscillator ChartArovella Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arovella Therapeutics Ltd. The current cci is 52.78.

Arovella Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartArovella Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arovella Therapeutics Ltd. The current cmo is 18.51.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arovella Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartArovella Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arovella Therapeutics Ltd. The current willr is -20.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Arovella is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Arovella Therapeutics Ltd Daily Williams %R ChartArovella Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arovella Therapeutics Ltd.

Arovella Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arovella Therapeutics Ltd. The current atr is 0.01006201.

Arovella Therapeutics Ltd Daily Average True Range (ATR) ChartArovella Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arovella Therapeutics Ltd. The current obv is 170,185,107.

Arovella Therapeutics Ltd Daily On-Balance Volume (OBV) ChartArovella Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arovella Therapeutics Ltd. The current mfi is 41.85.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Arovella Therapeutics Ltd Daily Money Flow Index (MFI) ChartArovella Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arovella Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Arovella Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arovella Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.230
Ma 20Greater thanMa 500.185
Ma 50Greater thanMa 1000.166
Ma 100Greater thanMa 2000.158
OpenGreater thanClose0.187
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arovella with someone you think should read this too:
  • Are you bullish or bearish on Arovella? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arovella? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arovella Therapeutics Ltd

I send you an email if I find something interesting about Arovella Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Arovella Therapeutics Ltd.

Receive notifications about Arovella Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.